Follette D B, Kerr D, Nasca T J, Euler H H, Pinevich A J
Department of Medicine, Mercy Hospital of Pittsburgh, Pennsylvania 15219-5166.
J Appl Physiol (1985). 1993 Dec;75(6):2820-4. doi: 10.1152/jappl.1993.75.6.2820.
Therapeutic apheresis as applied to humans may encompass a single treatment or numerous treatments for disorders ranging from acute poisoning to severe chronic autoimmune disease. However, the mechanisms of beneficial effects of apheresis are not well characterized. Utilizing a miniaturized hollow-fiber membrane system, we have developed a reliable technique for long-term vascular access in the rat that permits repetitive plasmapheresis. We established vascular access in 14 animals, with 8 and 6 rats randomized to 3- and 7-wk experimental periods, respectively. Immunoglobulin levels of blood samples obtained immediately before and after each plasmapheresis were measured to examine membrane filtration characteristics. Overall, 100% of the animals survived and 93% successfully completed their assigned experimental periods. Mean decrease of immunoglobulin G and M levels for 28 plasmapheresis treatments in five rats was 66.9 +/- 8.1 and 61.0 +/- 7.3% (SD), respectively, indicating effective membrane filtration. This model of apheresis can be applied to several disorders in the rat, including, but not limited to, spontaneous insulin-dependent diabetes mellitus and experimental inflammatory bowel disease.
应用于人类的治疗性血液成分单采可能包括针对从急性中毒到严重慢性自身免疫性疾病等各种病症的单次治疗或多次治疗。然而，血液成分单采有益效果的机制尚未得到充分表征。利用一种小型化中空纤维膜系统，我们开发了一种在大鼠中建立长期血管通路的可靠技术，该技术允许重复进行血浆置换。我们在14只动物中建立了血管通路，分别将8只和6只大鼠随机分配到3周和7周的实验期。测量每次血浆置换前后立即采集的血样中的免疫球蛋白水平，以检查膜过滤特性。总体而言，100%的动物存活，93%成功完成了指定的实验期。五只大鼠进行28次血浆置换治疗后，免疫球蛋白G和M水平的平均下降分别为66.9±8.1%和61.0±7.3%（标准差），表明膜过滤有效。这种血液成分单采模型可应用于大鼠的多种病症，包括但不限于自发性胰岛素依赖型糖尿病和实验性炎症性肠病。
